CN
CN
CN
1-22 of 192 result
CPHI

News Sep 01, 2026

Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026

CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.

NewslettersAug 31, 2026

Porton Newsletter - August 2026 Recap

Porton Newsletter - August 2026 Recap

News Aug 05, 2026

Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.

NewslettersJul 31, 2026

Porton Newsletter - July 2026 Recap

Porton Newsletter - July 2026 Recap

News Jul 08, 2026

Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

News Jul 03, 2026

Porton Delivers Dual-Payload ADC IND, Advancing Next-generation Conjugate Drug Development

Porton One-stop Biologics and Conjugates CDMO Platform successfully completed the full-cycle delivery of process development and GMP IND clinical sample manufacturing for a dual-payload ADC.

News Jul 02, 2026

Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR's 30th Anniversary

Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR’s 30th Anniversary

NewslettersJun 30, 2026

Porton Newsletter - June 2026 Recap

Porton Newsletter - June 2026 Recap

News Jun 25, 2026

Porton Concludes Productive Presence at CPHI China 2026

Porton Pharma Solutions Ltd. (“Porton”) wrapped up a productive three-day presence at CPHI China 2026, which was held from June 16 to 18 at the Shanghai New International Expo Centre.

Become part of Porton's community to access personalized insights and resources.
Subscribe for the Newsletter
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton's community to access personalized insights and resources.
Submit
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200